New clinical trial tests safety and efficacy of combination therapy in ovarian cancer and other women's malignancies


The Center for Cancer Research has opened a new clinical trial in ovarian cancer that will test the safety and efficacy a therapy combining two drugs. The phase I trial will test a combination therapy for ovarian, fallopian tube, and peritoneal cancers and is enrolling patients at the NIH Clinical Center. Ovarian cancer is a leading cause of cancer death in women and this study will combine two interferon (IFN) drugs, Sylatron (IFN-alpha) and Actimmune (IFN-gamma), with monocytes (white blood cells). Monocytes slow tumor growth while IFNs help immune cells, such as monocytes, fight cancer. The aim of this study is to see how this combination therapy affects tumor cells after efficacy was shown in preclinical studies. Led by Dr. Christina Annunziata, a physician-scientist in CCR's Women’s Malignancies Branch.  Annunziata hopes the new treatment will boost the patient’s own immune system to attack the cancer cells by delivering the therapy directly to the location of the cells in the abdominal cavity.  The trial will be held at the NIH Clinical Center in Bethesda, Maryland. View more information about this trial.

Summary Posted: 11/2016